ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV
Shots:
- Shionogi to receive $27.2M up front- $20.4M upon the achievement of a clinical milestone along with royalties on net sales of S-365598 (HIV integrase inhibitor) & will provide the development costs up to an annual maximum
- The collaboration will advance ViiV Healthcare's pipeline for HIV treatment. The therapy has the potential for use in ultra long-acting HIV regimens with dosing intervals of ≥3mos.
- The preliminary data showed that S-365598 has a high genetic barrier and a resistance profile that are distinct from dolutegravir and cabotegravir. Additionally- both companies plan to initiate human studies of S-365598 by 2023
| Ref: ViiV | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com